Rapport Therapeutics Inc.
Clinical trials sponsored by Rapport Therapeutics Inc., explained in plain language.
-
New pill could cut seizures in half for epilepsy patients
Disease control Recruiting nowThis study tests an experimental drug, RAP-219, in 333 adults with focal seizures (a type of epilepsy). Participants will take the drug or a placebo for several weeks to see if it safely reduces how often seizures happen. The goal is to find a new treatment option for people whos…
Phase: PHASE3 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 04:01 UTC
-
New hope for tough seizures: RAP-219 safety trial opens
Disease control Recruiting nowThis study tests the long-term safety of an experimental drug called RAP-219 in 30 adults with refractory focal epilepsy—seizures that don't respond well to current treatments. Participants must have completed a prior RAP-219 study. The main goal is to track side effects, while a…
Phase: PHASE2 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New drug RAP-219 aims to tame manic episodes in bipolar i disorder
Symptom relief Recruiting nowThis study tests an investigational drug called RAP-219 for people with bipolar I disorder who are currently experiencing a manic episode. The goal is to see if RAP-219 can safely reduce manic symptoms compared to a placebo. About 250 participants will take either the drug or a p…
Phase: PHASE2 • Sponsor: Rapport Therapeutics Inc. • Aim: Symptom relief
Last updated May 17, 2026 03:57 UTC